LANCL2-based anti diabetic compounds (Bio Therapeutics)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameLANCL2-based anti diabetic compounds (Bio Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionLanC-like protein 2 modulators
TargetsLanC-like protein 2
Therapy Area/IndicationsInflammationDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesBio Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesBio Therapeutics
Active IndicationsN/A
Inactive IndicationsInflammationDiabetes Mellitus

Other Information

ATC CodeN/A
Related LinksN/A